Category: COVID-19

Respiratory Virus Vaccine Recommendations

Posted on by

The American Academy of Family Practioners (AAFP), the American Academy of Pediatrics (AAP), the American Medical Association (AMA), the Vaccine Integrity Project (VIP), the American College of Obstetrics and Gynecology (ACOG), and the Infectious Disease Society of America (IDSA) have put together Respiratory Virus Immunization Recommendations. https://www.ama-assn.org/system/files/respiratory-virus-immunization-recommendations.pdf Have a gander, and tell your friends!

Vaccine Integrity Project and American Medical Association Announces Independent 2026-2027 Respiratory Season Vaccine Evidence Review

Posted on by

Tuesday, September 2. The Vaccine Integrity Project, in collaboration with the American Medical Association (AMA), today announced its independent, 2026-27 respiratory season vaccine evidence review, assessing the safety and effectiveness of respiratory virus season immunizations. The latest, high-quality scientific evidence found that immunizations against influenza, COVID-19 and respiratory syncytial virus (RSV) continue to provide meaningful protection against severe illness, hospitalization and death. The Vaccine Integrity Project undertook the review to both analyze effectiveness but also to look for any safety signals that may have emerged in the data gathered since its last evidence review in summer 2025. Reassuringly, researchers found Read More …

Meyer, DPH Standing Order to Protect Vaccine Access

Posted on by

On Wednesday, September 10, Governor Matt Meyer and the Delaware Division of Public Health issued a standing order on COVID-19 vaccine eligibility and are calling on the Board of Pharmacy to convene an emergency meeting to protect vaccine access. “Vaccines save lives. Science, not politics, will guide how we keep our communities safe,” said Governor Matt Meyer. “With this standing order and our partnership with neighboring states, we are taking control of our future, ensuring that every Delawarean has access to the protection they need.” The standing order refers to recommendations from other relevant professional organizations to determine eligibility for the COVID-19 vaccine. Read More …

AAP: Recommendations for COVID-19 Vaccines

Posted on by

On August 19, the American Academy of Pediatrics Committee on Infectious Diseases provided the following recommendations for Infants, Children, and Adolescents and COVID-19 Vaccines. [See policy statement.] Infants and children 6-23 months of age who do not have contraindications should receive 2025-2026 COVID-19 vaccine Children 6 months – 18 years of age who are moderately or severely immunocompromised require 2+ doses of age-appropriate 2025-2026 COVID-19 vaccine depending on previous vaccination status A single dose of age-appropriate 2025-2026 COVID-19 vaccine is recommended for all children and adolescents 2-18 years in the following high risk groups (regardless of prior COVID-19 vaccination status) Read More …

COVID’s Evolutionary Journey

Posted on by

Pekar, J.E., Lytras, S., Ghafari, M., Magee, A.F., Parker, E., Wang, Y., …, Lemey, P. (2025). The recency and geographical origins of the bat viruses ancestral to SARS-CoV and SARS-CoV-2. Cell, online. Summary: The emergence of SARS-CoV in 2002 and SARS-CoV-2 in 2019 led to increased sampling of sarbecoviruses circulating in horseshoe bats. Employing phylogenetic inference while accounting for recombination of bat sarbecoviruses, we find that the closest-inferred bat virus ancestors of SARS-CoV and SARS-CoV-2 existed less than a decade prior to their emergence in humans. Read more

FDA Approves and Authorizes 2024-2025 COVID-19 Vaccines

Posted on by

FDA Approves and Authorizes Updated mRNA COVID-19 Vaccines to Better Protect Against Currently Circulating Variants August 22, 2024 – Today, the U.S. Food and Drug Administration approved and granted emergency use authorization (EUA) for updated mRNA COVID-19 vaccines (2024-2025 formula) to include a monovalent (single) component that corresponds to the Omicron variant KP.2 strain of SARS-CoV-2. The mRNA COVID-19 vaccines have been updated with this formula to more closely target currently circulating variants and provide better protection against serious consequences of COVID-19, including hospitalization and death. Today’s actions relate to updated mRNA COVID-19 vaccines manufactured by ModernaTX Inc. and Pfizer Read More …

FDA Updates Advice to 2024-2025 COVID-19 Formula

Posted on by

Based on the totality of the evidence, on June 6, 2024, FDA initially advised the manufacturers of the licensed and authorized COVID-19 vaccines that the COVID-19 vaccines (2024-2025 Formula) for use in the United States beginning in fall 2024 should be monovalent JN.1 vaccines. FDA has continued to monitor the circulating strains of SARS-CoV-2.  Based on the most current available data, along with the recent rise in cases of COVID-19 in areas of the country, the agency has further determined that the preferred JN.1-lineage for the COVID-19 vaccines (2024-2025 Formula) is the KP.2 strain, if feasible. Read more

Moderna Receives U.S. FDA Approval for RSV Vaccine mRESVIA(R)

Posted on by

May 31, 2024 CAMBRIDGE, MA / ACCESSWIRE / May 31, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and Drug Administration (FDA) has approved mRESVIA (mRNA-1345), an mRNA respiratory syncytial virus (RSV) vaccine, to protect adults aged 60 years and older from lower respiratory tract disease caused by RSV infection. The approval was granted under a breakthrough therapy designation and marks the second approved mRNA product from Moderna. “The FDA approval of our second product, mRESVIA, builds on the strength and versatility of our mRNA platform,” said Stéphane Bancel, Chief Executive Officer of Moderna. “mRESVIA protects older adults Read More …